{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-21-055781","form_type":"8-K","ticker":"LTRN","cik":"0001763950","company_name":"Lantern Pharma Inc.","filed_at":"2021-11-01T23:59:59+00:00","discovered_at":"2026-05-14T18:04:14.031237+00:00","generated_at":"2026-06-28T15:50:09.684506+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Lantern Pharma Q3 net loss $4.05M, cash $73.8M; RADR hits 10B datapoints, LP-184 ODD","bullets":["Net loss $4.05M ($0.36 per share) vs $1.70M in Q3 2020; R&D expenses $2.96M up from $0.60M.","Cash and marketable securities $73.8M as of Sep 30, 2021, up from $19.2M at Dec 31, 2020.","RADR platform surpassed 10 billion curated oncology data points, up from 4.6B in earlier 2021.","LP-184 received Orphan Drug Designation from FDA for pancreatic cancer and glioblastoma.","Announced strategic collaborations with Deep Lens and Code Ocean; planning Phase 2 trial for LP-300."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-21-055781","json":"https://secwatch.observer/filing/0001213900-21-055781.json","markdown":"https://secwatch.observer/filing/0001213900-21-055781.md","text":"https://secwatch.observer/filing/0001213900-21-055781.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1763950/000121390021055781/0001213900-21-055781-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1763950/000121390021055781/ea149696-8k_lantern.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T15:50:09.684506+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}